GlassScriptPhysician profile
Edward J Parisi
NPI 1487664215
$14,653.39
in general payments reported to CMS, 2019-2025
64 companies · $3,478 in 2025
The $3,478 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,273 · 2020: $366 · 2021: $579 · 2022: $1,865 · 2023: $2,863 · 2024: $3,229 · 2025: $3,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,382 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,382.23 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,941.75 | 2019-2025 | |
| Novo Nordisk INC | $1,009.19 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $923.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Corcept Therapeutics | $908.96 | 2020-2025 | Korlym |
| Amgen INC. | $881.37 | 2019-2025 | Repatha, Evenity, Prolia |
| Pfizer INC. | $809.61 | 2019-2025 | |
| Lilly USA, LLC | $688.37 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.99 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $557.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $522.81 | 2019-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $482.88 | 2019-2025 | |
| Astellas Pharma US INC | $462.38 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $410.81 | 2021-2025 | |
| Daiichi Sankyo INC. | $335.17 | 2023-2025 | Injectafer |
| Amarin Pharma, INC. | $328.05 | 2019-2023 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Parisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.